Diagnostic role of fluorodeoxyglucose PET in breast cancer: A history to current application Journal Article
| Authors: | Chakraborty, D.; Basu, S.; Ulaner, G. A.; Alavi, A.; Kumar, R. |
| Article Title: | Diagnostic role of fluorodeoxyglucose PET in breast cancer: A history to current application |
| Abstract: | Histologic subtype, receptor status, and other biologic factors greatly affect the avidity of breast malignancy on fluorodeoxyglucose (FDG) PET. FDG PET/computed tomography (CT) has demonstrated excellent value in the evaluation of extra-axillary nodal and distant metastases. Patients with early-stage breast cancers do not benefit from FDG PET/CT; however, unsuspected distant metastases may be revealed by systemic staging of locally advanced breast cancers by FDG PET/CT, and this has substantial impact on patient management. FDG PET/CT has demonstrated value in the evaluation of treatment response and in detection of disease recurrence. © 2018 Elsevier Inc. |
| Keywords: | treatment response; review; cancer recurrence; patient selection; cancer adjuvant therapy; cancer staging; nuclear magnetic resonance imaging; positron emission tomography; lymph node metastasis; antineoplastic agent; cancer grading; diagnostic accuracy; sensitivity and specificity; breast cancer; distant metastasis; liver metastasis; diagnostic value; cancer classification; fluorodeoxyglucose; positron emission tomography (pet); pet/ct; lobular carcinoma; cancer prognosis; human; priority journal; early cancer diagnosis; positron emission tomography-computed tomography; fluorodeoxyglucose (fdg); positron emission tomography magnetic resonance |
| Journal Title: | PET Clinics |
| Volume: | 13 |
| Issue: | 3 |
| ISSN: | 1556-8598 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2018-07-01 |
| Start Page: | 355 |
| End Page: | 361 |
| Language: | English |
| DOI: | 10.1016/j.cpet.2018.02.011 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 August 2018 -- Source: Scopus |
